BT02

DRUG3 trials

Sponsors

Biotroy Therapeutics

Conditions

Advanced Lung CancerAdvanced Malignant Solid TumorAdvanced MelanomaAdvanced Solid TumorLeukemiaLymphomaMultiple Myeloma (MM)Non-Small Cell Lung Cancer

Phase 1

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Not yet recruitingNCT07107204

Biotroy TherapeuticsLeukemia, Lymphoma, Multiple Myeloma (MM) +1

Start: 2025-10-31End: 2028-04-30Target: 116Updated: 2025-09-17

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

Not yet recruitingNCT07107178

Biotroy TherapeuticsAdvanced Melanoma, Advanced Solid Tumor

Start: 2025-08-08End: 2027-08-31Target: 58Updated: 2025-08-06

A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer

Not yet recruitingNCT07110363

Biotroy TherapeuticsAdvanced Lung Cancer, Advanced Malignant Solid Tumor, Non-Small Cell Lung Cancer +1

Start: 2025-08-31End: 2027-05-31Target: 58Updated: 2025-08-07